

| POLICY NAME | Policy #: | POLICY # | The purpose of this policy is to define coverage criteria for Oxlumo (luma |
|-------------|-----------|----------|--|
|-------------|-----------|----------|--|

Criteria

Coverage Criteria

- ☐ Documented diagnosis of primary hyperoxaluria type 1 based on both of the following:
 - Confirmed genetic testing of AGXT or AGT mutation
 - Metabolic testing demonstrating ONE of the following: o Increased urinary oxalate excretion (greater than 1 mmol/1.73m² per day [90mg/1.73m² per day], increased urinary oxalate:creatinine ratio relative to normative values for age); OR o Increased plasma oxalate and glyoxylate concentrations
- ☐ Patient does not have a history of liver or kidney transplant
- ☐ Patient has tried pyridoxine for at least 3 months with no significant improvement
- ☐ Ordered by, or in consultation with a nephrologist (kidney doctor) or urologist (doctor of the urinary tract) or medical gene doctor
- ☐ Review of chart notes documenting diagnosis and confirming that patient has met all above requirements for treatment with Oxlumo by both a pharmacist and medical director